INHIBITION OF GLUCOSE LOWERING EFFECT OF SITAGLIPTIN ON CONCURRENT USE WITH AMLODIPINE ON ADRENALINE INDUCED HYPERGLYCEMIC CARDIOTOXIC RAT
Objective- Sitagliptin is the first and only prescription medication in a new class of oral antihyperglycemic agents, which enhance the body's own ability to lower blood glucose when it is elevated. As many diabetic hypertensive patients taking amlodipine, the present study was undertaken to explore the effect of amlodipine on glucose lowering effect of Sitagliptin on adrenaline induced hyperglycemic cardiotoxic rats.
Methods- Both acute and chronic effect of the drug combination was studied on adrenaline induced hyperglycemic cardiotoxic rats. In acute study, only glucose level was observed whereas in chronic study both glucose and lactate dehydrogenase (LDH) was estimated and heart was subjected to histopathological examination.
Result- The glucose levels were increased significantly (p<.05) in adrenaline induced rats. Sitagliptin displayed significant reduction in rise in glucose level. The glucose level also significantly increased in rats where both Sitagliptin and amlodipine administered in both acute and chronic study. The rise in LDH level was also more in combination group in comparison to Sitagliptin alone.
Conclusion- From the present study, it can be concluded that amlodipine inhibits glucose lowering effect of Sitagliptin in adrenaline induced hyperglycemic cardiotoxic rats.
Keywords- Sitagliptin, Amlodipine, adrenaline, glucose, cardiotoxicity.
2. Ramachandran A, Das AK, Current Status of Diabetes in India and Need for Novel Therapeutic Agents. Journal of Association of Physician of India 2010; 58(supplement): 7-9.
3. American Diabetes Association, Treatment of hypertension in adults with Diabetes. Diabetes Care 2003; 26 (Suppl. 1): S80-S82.
4. Bakris GL, Sowers JR, Treatment of Hypertension in Patients with Diabetesâ€”An Update. The journal of clinical hypertension 2008; 10 (9):707- 711.
5. Kousalya K, Chirumamilla S, Manjunath S Prescribing trend of antihypertensive drugs in hypertensive and diabetic hypertensive patients. Asian Journal of Pharmaceutical and Clinical Research 2012; 5(4): 22-23.
6. Badyal DK, Kaur J. Sitagliptin: a New Class of Oral Drug for Type 2 Diabetes. JK Science 2008; 10 (2): 97-98.
7. Grodsky GM, Bennett LL, Cation requirements for insulin secretion in isolated perfused pancreas. Diabetes 1966; 15: 410-413.
8. Mandlik RV, Desai SK, Antidiabetic activity of polyherbal formulation (DRF/AY/5001). Indian journal of Experimental biology 2008; 46: 599-606.
9. Begum S, Akhter N, Cardioprotective effect of amlodipine in oxidative stress induced by experimental myocardial infarction in rats. Bangladesh J Pharmacol 2007; 2: 55-60.
10. Ferreira L, Pinto F, Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators of Inflammation 2010; 592760: 1-11
11. Srinivasan PS, Hakim ZS, Santani DD, Goyal RK Effects of chronic treatment with amlodipine in streptozotocin-diabetic and spontaneously hypertensive rats. Pharmacol. Res. 1997; 35: 423-428.
12. Hardman JG, Limbird LE. The Pharmacological basis of therapeutics, 10th Edition, McGraw Hill Medical Publication Division 2001; 860-862.
13. Murthy GK, Mayuren C. Influence of calcium channel antagonist on the Pharmacodynamics of a second-generation sulfonylurea in rats and rabbits, Asian J. Pharmaceutics 2008; 2: 163-166.
14. Gokhale MS, Shah DH , Hakim Z , Santani DD., Goyal RK., Effect of chronic treatment with amlodipine in non-insulin-dependent diabetic rats, Pharmacol. Res. 1998; 37: 455-459.
15. Deakin CD, Fagan EA. Cytoprotective effects of calcium channel blockers, mechanisms and potential applications in hepatocellular injury, J. Hepatol.1991; 12: 251-255.
16. Chattopadhyay P, Aher VD. Protective role of the calcium channel blocker amlodipine against mitochondrial injury in ischemia and reperfusion injuryof rat liver, Acta Pharm. 2008; 58: 421â€“428
17. Mason RP, Trumbore MW. Antioxidant properties of calcium antagonists related to membrane biophysical interactions, Am. J. Cardiol. 1999; 19:16L-22L.
18. Gerich JE, Lorenzi M. Studies on the Mechanism of Epinephrine-induced Hyperglycemia in Man: Evidence for Participation of Pancreatic Glucagon Secretion, Diabetes 1976; 25(1):65-71.
19. Tripathi KD, Essentials of Medical Pharmacology, Jaypee Brothers Medical Publishers(P) Ltd, New Delhi, India, 4th edition, 2001,122-124.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.